KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Shares Outstanding (Diluted Average) (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Shares Outstanding (Diluted Average) for 17 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 2.83% year-over-year to $1.2 billion, compared with a TTM value of $1.2 billion through Dec 2025, up 2.83%, and an annual FY2025 reading of $1.2 billion, up 2.83% over the prior year.
  • Shares Outstanding (Diluted Average) was $1.2 billion for Q4 2025 at Teva Pharmaceutical Industries, roughly flat from $1.2 billion in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $1.2 billion in Q3 2025 and bottomed at $1.1 billion in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) changed 0.0% in 2022, then grew 3.21% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $1.1 billion in 2021, then increased by 0.27% to $1.1 billion in 2022, then increased by 0.81% to $1.1 billion in 2023, then rose by 1.07% to $1.1 billion in 2024, then rose by 2.83% to $1.2 billion in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for TEVA at $1.2 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.2 billion in Q2 2025.